Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0000366

Isradipine

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H21N3O5
CAS Number:
75695-93-1
Molecular Weight:
371.39
MDL number:
MFCD00153820
UNSPSC Code:
41116107
PubChem Substance ID:
329830922
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

isradipine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C

InChI

1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3

InChI key

HMJIYCCIJYRONP-UHFFFAOYSA-N

Gene Information

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Isradipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R N Brogden et al.
Drugs, 49(4), 618-649 (1995-04-01)
Since the earlier review in Drugs substantial additional data have accumulated regarding the antihypertensive efficacy of isradipine in various clinical situations, as well as data on its clinical effects in atherosclerosis. Recent therapeutic trials confirm that the efficacy of isradipine
D G Vidt
Cleveland Clinic journal of medicine, 57(8), 677-684 (1990-11-01)
Isradipine (DynaCirc, PK 200-110) is a new calcium channel blocker of the dihydropyridine class. In controlled, double-blind, clinical trials isradipine is an effective first-line monotherapeutic agent in the treatment of hypertension, regardless of patient age or race. Isradipine is safe
D Blecker
Angiology, 45(12), 997-1008 (1994-12-01)
Treatment of hypertension in the complicated patient requires a specialized approach focusing on the treatment of the blood pressure and concurrent medical problems. Therapy must be chosen in consideration of the patient's age, multiple illnesses, declining organ function, and possible
H Sinzinger et al.
Journal of cardiovascular pharmacology, 19 Suppl 3, S29-S31 (1992-01-01)
Isradipine, a calcium antagonist of the dihydropyridine type, shows antiatherosclerotic actions that interfere with all three main mechanisms of atherosclerosis. These actions are mediated by the release of prostaglandin I2 and endothelium-derived relaxing factor, and the subsequent elevation of intracellular
H Miller
American journal of hypertension, 4(2 Pt 2), 135S-139S (1991-02-01)
Isradipine is a new dihydropyridine calcium antagonist shown to be efficacious, safe, and well tolerated in the treatment of hypertension, regardless of patient age or race. There has been no evidence of negative inotropism, atrioventricular conduction delay, nor clinically significant
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service